(NASDAQ: ZYME) Zymeworks's forecast annual revenue growth rate of 38.34% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.52%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.23%.
Zymeworks's revenue in 2026 is $81,263,000.On average, 14 Wall Street analysts forecast ZYME's revenue for 2026 to be $22,505,707,400, with the lowest ZYME revenue forecast at $17,540,139,252, and the highest ZYME revenue forecast at $28,171,566,703. On average, 13 Wall Street analysts forecast ZYME's revenue for 2027 to be $15,088,755,094, with the lowest ZYME revenue forecast at $9,374,700,571, and the highest ZYME revenue forecast at $26,362,055,252.
In 2028, ZYME is forecast to generate $15,710,911,574 in revenue, with the lowest revenue forecast at $8,484,549,458 and the highest revenue forecast at $23,845,680,570.